GlassScriptPhysician profile
Darla Pearce
NPI 1689761215
$8,048.48
in general payments reported to CMS, 2019-2025
50 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,295 · 2022: $1,481 · 2023: $1,587 · 2024: $2,169 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,272.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,304.29 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $1,069.21 | 2021-2025 | |
| Novo Nordisk INC | $933.58 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $415.86 | 2021-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $380.88 | 2022-2025 | Rexulti, Brintellix |
| Pfizer INC. | $372.41 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $321.80 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $316.35 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $275.15 | 2024-2025 | Auvelity, Symbravo |
| Corium, LLC | $230.67 | 2022-2025 | Azstarys, Azstarys |
| Optinose US, INC. | $219.61 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $201.79 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.22 | 2022-2025 | |
| Tris Pharma INC | $152.93 | 2022-2024 | Dyanavel Xr |
| Alkermes, INC. | $139.41 | 2022-2025 | Aristada, Lybalvi |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darla Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.